Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 ...
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. SNSE, an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a …